Search Results

You are looking at 1 - 10 of 143 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

Counterpoint: Prostate-Specific Antigen Velocity Is Not of Value for Early Detection of Cancer

Andrew J. Vickers

With prostate-specific antigen (PSA) velocity, as in all areas of clinical research, the first question should be, “What is the question?” It cannot reasonably be doubted that PSA velocity is statistically associated with prostate cancer outcomes

Full access

Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level

Vinayak Muralidhar, Paul L. Nguyen, Brandon A. Mahal, David D. Yang, Kent W. Mouw, Brent S. Rose, Clair J. Beard, Jason A. Efstathiou, Neil E. Martin, Martin T. King, and Peter F. Orio III

Background Initial treatment of prostate cancer is driven by clinical risk factors, including T stage, Gleason score, and prostate-specific antigen (PSA) level, in addition to assessment of regional nodal or distant spread. 1 In men with

Full access

Point: Impact of Prostate-Specific Antigen Velocity on Management Decisions and Recommendations

Stacy Loeb and H. Ballentine Carter

Although prostate cancer screening with prostate-specific antigen (PSA) has been shown to reduce metastases and mortality from prostate cancer, 1 , 2 its use has numerous drawbacks. A key issue is its limited specificity for clinically

Full access

Prostate Cancer Screening and Determining the Appropriate Prostate-Specific Antigen Cutoff Values

William J. Catalona and Stacy Loeb

T he prostate-specific antigen (PSA) blood test is the foundation for modern prostate cancer (CaP) screening. Initially it was used in forensic medicine. The subsequent discovery that it could be measured in serum, and that serum levels increase

Full access

Enrollment Criteria Controversies for Active Surveillance and Triggers for Conversion to Treatment in Prostate Cancer

David D. Buethe and Julio Pow-Sang

The year 2012 marks the 10th anniversary of the initial reporting of active surveillance (AS) as a management strategy for low-risk prostate cancer. 1 , 2 Since the widespread use of prostate-specific antigen (PSA) beginning in the early 1990s

Full access

Financial Toxicity and Its Association With Prostate and Colon Cancer Screening

Michael J. Herriges Jr, Rachel Shenhav-Goldberg, Juliet I. Peck, Sumeet K. Bhanvadia, Alicia Morgans, Fumiko Chino, Thenappan Chandrasekar, Oleg Shapiro, Joseph M. Jacob, Alina Basnet, Gennady Bratslavsky, and Hanan Goldberg

screening tests for prostate and colon cancers. The American Urologic Association guidelines recommend screening for prostate cancer with a prostate-specific antigen (PSA) blood test from ages 55 to 69 years at a frequency of every 2 years or more often. 15

Full access

Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer–Specific Mortality

Brandon A. Mahal, Ming-Hui Chen, Andrew A. Renshaw, Marian J. Loffredo, Philip W. Kantoff, and Anthony V. D'Amico

deprivation therapy (ADT) are often curative treatments for localized disease, 2 – 5 approximately one-quarter of patients will experience recurrence within 10 years after curative-intent therapy. 6 , 7 An increasing prostate-specific antigen (PSA) level

Full access

PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes

Christopher J. Magnani, Kevin Li, Tina Seto, Kathryn M. McDonald, Douglas W. Blayney, James D. Brooks, and Tina Hernandez-Boussard

during the patient’s lifetime. Autopsy studies detect prostate cancer in 30% of men by age 55 years and 60% of men by age 80 years. 3 Widespread implementation of prostate-specific antigen (PSA) screening has led to a significant increase in diagnosis

Full access

Role of Complexed PSA in the Early Detection of Prostate Cancer

Yoshio Naya and Koji Okihara

. CA Cancer J Clin 2003 ; 53 : 5 – 26 . 2 Catalona WJ Smith DS Ratliff TL . Measurement of prostate-specific antigen in serum as a screening test for prostate cancer . N Engl J Med 1991 ; 324 : 1156 – 1161 . 3 Babaian RJ

Full access

Intermittent Versus Continuous Androgen Deprivation Therapy

Celestia S. Higano

conferred the same toxicity as orchiectomy. After the test for prostate-specific antigen (PSA) was approved by the FDA in 1986, a new population of men was identified who had no evidence of metastatic disease other than an increasing PSA level after primary